Nilvanstomig clinical trials
Also written ZG005.
How each study uses nilvanstomig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nilvanstomig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2025 (8)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 4 |
| 2025 | 8 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Jaktinib (2) · Bevacizumab (1) · Tislelizumab (1) · Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18 (1) · Alveltamig (1) · Sintilimab (1) · Donafenib tosylate (1) · Donafenib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test nilvanstomig.
- Apr 2027Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Apr 2027Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- May 2027Study of ZG005 in Patients With Advanced Solid TumorsPhase 2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- May 2027Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Aug 2027Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Sep 2027ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Oct 2027Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Studies
Open first, then newest update. How each study uses nilvanstomig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularRecruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07813572Written as ZG005 for Injection
- ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07833839Written as ZG005 for Injection
- Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract CarcinomaRecruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07099547Written as ZG005
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06903377Written as ZG005 for Injection
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06883526Written as ZG005 for Injection
- Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06938880Written as ZG005 for Injection
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07038096Written as ZG005
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07080216Written as ZG005
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07142837Written as ZG005
- Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaRecruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06558227Written as ZG005 for Injection
- Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.RecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06372626Written as ZG005
- Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06241235Written as ZG005 Powder for Injection
- A Study of ZG005 in Patients With Advanced Solid TumorsCompletedPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06233292Written as ZG005 Powder for Injection
- Study of ZG005 in Patients With Advanced Solid TumorsActive, not recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06927687Written as ZG005 for Injection
- A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06239298Written as ZG005 Powder for Injection
Given beside what is tested · 1 — nilvanstomig is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call nilvanstomig · ClinicalTrials.gg INT014504
- UNII (FDA) 2NQG7P8ET6NILVANSTOMIGOne source FDA
- NCI Thesaurus C208073NilvanstomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2NQG7P8ET6 | NILVANSTOMIG | One source FDA |
| NCI Thesaurus | C208073 | Nilvanstomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.